ProCE Banner Activity

My Thoughts on the Evolving Role of Immunotherapy for SCLC

Clinical Thought
Read this commentary to gain expert perspective on the role of immunotherapy for patients with extensive-stage SCLC.

Released: April 04, 2019

Expiration: April 02, 2020

No longer available for credit.

Share

Faculty

Stephen Liu

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech TEXT Only

Faculty Disclosure

Primary Author

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Stephen V. Liu, MD, has disclosed that he has received funds for research support from AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Clovis, Corvus, Esanex, Genentech/Roche, Lilly, Lycera, Merck, Molecular Partners, OncoMed, Rain Therapeutics, Pfizer, and Threshold and consulting fees from Apollomics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, Heron, Janssen, Lilly, Merck, Pfizer, Regeneron, Taiho, and Takeda.